The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A nationwide population-based study comparing survival in unresectable advanced or synchronous metastatic esophageal and gastric adenocarcinoma.
 
Marieke Pape
Research Funding - Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst)
 
Pauline A.J. Vissers
No Relationships to Disclose
 
David Bertwistle
Employment - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Lilly; Lilly; Lilly; Lilly; United Health Group; United Health Group; United Health Group; United Health Group
Patents, Royalties, Other Intellectual Property - St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
 
Laura McDonald
Employment - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb
 
Hanneke W.M. Van Laarhoven
Honoraria - Lilly/ImClone; Lilly/ImClone; Lilly/ImClone; Lilly/ImClone
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Lilly/ImClone; Lilly/ImClone; Lilly/ImClone; Lilly/ImClone; Nordic Group; Nordic Group; Nordic Group; Nordic Group; Servier; Servier; Servier; Servier
Research Funding - Bayer Schering Pharma (Inst); Bayer Schering Pharma (Inst); Bayer Schering Pharma (Inst); Bayer Schering Pharma (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Janssen-Cilag (Inst); Janssen-Cilag (Inst); Janssen-Cilag (Inst); Janssen-Cilag (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Nordic Group (Inst); Nordic Group (Inst); Nordic Group (Inst); Nordic Group (Inst); Philips Healthcare (Inst); Philips Healthcare (Inst); Philips Healthcare (Inst); Philips Healthcare (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Servier (Inst); Servier (Inst); Servier (Inst); Servier (Inst)
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca
 
Rob H. A. Verhoeven
Research Funding - Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst)